The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...
Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...
Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...
The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...
The "Hims and Hers" commercial railed against the weight loss industry and promoted the company's weight loss drug offerings as a less costly option compared to brand-name drugs. ABC News chief ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results